Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

Chris2bucks4life Jun. 25 at 4:52 PM

$GANX xbi up 84 percent ytd and we are at 2 percent

1 · Reply

Gmaggyfillup Jun. 25 at 4:24 PM

$GANX hate to throw this out there can you imagine waiting all this time , then something not working out , and completely getting wiped out here ?

4 · Reply

marvessa Jun. 25 at 3:19 PM

$GANX look at the one week xbi chart vs our 🙄

1 · Reply

MQuick Jun. 25 at 3:03 PM

$GANX this is the largest single position ive ever held in my life 🫣😅

0 · Reply

MQuick Jun. 25 at 2:27 PM

$GANX this price is ludicrous

1 · Reply

Chris2bucks4life Jun. 25 at 2:25 PM

$GANX 400 more at the market your welcome

1 · Reply

Layne_Thomas_Staley Jun. 25 at 1:58 PM

$GANX Here's your bear case. Not a joke.

1 · Reply

MQuick Jun. 25 at 1:25 PM

$GANX 45k on the offer OK lol

1 · Reply

Layne_Thomas_Staley Jun. 25 at 12:40 PM

$GANX Please forward your bitching to our current administration. DOGE prefers crypto grifting to revolutionary science.

1 · Reply

MQuick Jun. 25 at 12:27 PM

$GANX if i keep buying i might be elected to the board

1 · Reply

Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

Jun 10, 2026, 7:00 AM EDT - 15 days ago

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Jun 9, 2026, 7:00 AM EDT - 16 days ago

Gain Therapeutics Slides: Corporate presentation

2026-05-26T14:58:26.000Z - 4 weeks ago

Gain Therapeutics presents data from Phase 1b study of GT-02287

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

2026-05-12T19:29:06.000Z - 6 weeks ago

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Gain Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 6 weeks ago

Gain Therapeutics Quarterly report: Q1 2026

2026-05-11T11:47:50.000Z - 6 weeks ago

Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Gain Therapeutics Slides: Corporate presentation

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Gain Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Gain Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:30 AM EDT - 2 months ago

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

2026-04-17T16:20:14.000Z - 2 months ago

Gain Therapeutics management to meet with Maxim

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Gain Therapeutics Slides: Corporate presentation

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 3 months ago

Gain Therapeutics Earnings release: Q4 2025

2026-03-26T11:26:07.000Z - 3 months ago

Gain Therapeutics reports Q4 EPS (61c), consensus (14c)

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Mar 24, 2026, 1:30 PM EDT - 3 months ago

Gain Therapeutics Transcript: The 38th Annual Roth Conference

Mar 19, 2026, 4:57 PM EDT - 3 months ago

Gain Therapeutics to Present at the 38th Annual ROTH Conference

2026-03-18T12:38:06.000Z - 3 months ago

Gain announces presentations on Phase 1b clinical study of GT-02287

Mar 18, 2026, 8:15 AM EDT - 3 months ago

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

2026-03-12T11:32:59.000Z - 3 months ago

Gain Therapeutics provides regulatory update on GT-02287

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Mar 8, 2026, 7:00 AM EDT - 3 months ago

Gain Therapeutics Slides: Corporate presentation

Feb 19, 2026, 7:00 AM EST - 4 months ago

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 7, 2026, 7:00 AM EST - 6 months ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 10:00 AM EST - 6 months ago

Gain Therapeutics Transcript: Study Update

Jan 6, 2026, 10:00 AM EST - 6 months ago

Gain Therapeutics Press release: Study Update

2026-01-06T12:26:07.000Z - 6 months ago

Gain Therapeutics provides additional data from Phase 1b study of GT-02287

Jan 6, 2026, 7:00 AM EST - 6 months ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

2025-12-30T16:00:13.000Z - 6 months ago

Gain Therapeutics holds a conference call

2025-12-19T18:35:13.000Z - 6 months ago

Gain Therapeutics price target raised to $10 from $6 at Roth Capital

Dec 18, 2025, 4:05 PM EST - 6 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

2025-12-18T12:10:20.000Z - 6 months ago

Gain Therapeutic announces Phase 1b study of GT-02287 met prespecified endpoint

Dec 18, 2025, 7:00 AM EST - 6 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

2025-11-20T12:05:27.000Z - 7 months ago

Gain Therapeutics presents data on GT-02287

Nov 20, 2025, 7:00 AM EST - 7 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

2025-11-12T12:15:51.000Z - 8 months ago

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

Gain Therapeutics Registration statement: Registration Filing

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Gain Therapeutics to Present at Neuroscience 2025

2025-10-16T11:45:35.000Z - 9 months ago

Gain Therapeutics price target lowered to $5 from $9 at BTIG

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 14, 2025, 4:00 PM EDT - 9 months ago

Gain Therapeutics Transcript: Study Result

2025-10-07T13:10:58.000Z - 9 months ago

Gain Therapeutics price target raised to $7 from $5 at Maxim

2025-10-06T12:36:01.000Z - 9 months ago

Gain Therapeutics presents initial data from Phase 1b study of GT-02287

Oct 6, 2025, 8:15 AM EDT - 9 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 9 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

2025-09-18T11:50:28.000Z - 10 months ago

Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s

Sep 18, 2025, 7:41 AM EDT - 10 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

2025-09-04T12:21:10.000Z - 10 months ago

Gain Therapeutics receives Australian approval of Phase 1b dosing extension

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Gain Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Gain Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 1 year ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 1 year ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 1 year ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 28, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Registration statement: Registration Filing

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Gain Therapeutics Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 1 year ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Gain Therapeutics Proxy statement: Proxy Filing

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Annual report: Q4 2024

Mar 27, 2025, 1:30 PM EDT - 1 year ago

Gain Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 12:00 AM EST - 1 year ago

Gain Therapeutics Earnings release: Q3 2024

Oct 15, 2024, 12:00 PM EDT - 1 year ago

Gain Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Gain Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 8:30 AM EDT - 2 years ago

Gain Therapeutics Transcript: Status Update

Jun 28, 2024, 4:39 PM EDT - 2 years ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 2 years ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Chris2bucks4life Jun. 25 at 4:52 PM

$GANX xbi up 84 percent ytd and we are at 2 percent

1 · Reply

Gmaggyfillup Jun. 25 at 4:24 PM

$GANX hate to throw this out there can you imagine waiting all this time , then something not working out , and completely getting wiped out here ?

4 · Reply

marvessa Jun. 25 at 3:19 PM

$GANX look at the one week xbi chart vs our 🙄

1 · Reply

MQuick Jun. 25 at 3:03 PM

$GANX this is the largest single position ive ever held in my life 🫣😅

0 · Reply

MQuick Jun. 25 at 2:27 PM

$GANX this price is ludicrous

1 · Reply

Chris2bucks4life Jun. 25 at 2:25 PM

$GANX 400 more at the market your welcome

1 · Reply

Layne_Thomas_Staley Jun. 25 at 1:58 PM

$GANX Here's your bear case. Not a joke.

1 · Reply

MQuick Jun. 25 at 1:25 PM

$GANX 45k on the offer OK lol

1 · Reply

Layne_Thomas_Staley Jun. 25 at 12:40 PM

$GANX Please forward your bitching to our current administration. DOGE prefers crypto grifting to revolutionary science.

1 · Reply

MQuick Jun. 25 at 12:27 PM

$GANX if i keep buying i might be elected to the board

1 · Reply

Jwa68 Jun. 25 at 12:25 PM

$GANX Remember, you always have the option to simply sell and move on. Why anyone would do that now is beyond me, but always do what is in your own best interest and do your own due diligence. There are pleanty of others willing to take your shares off your hands at this level. There is also more than enough outside of what is said here for you to make a fair and balanced independent assessment. KOL's, 5 analysts, MJFF, Parkinson's News Daily etc. None post on Stocktwits and all are subject matter experts. We have a drug and stocks can reprice violently and overnight. If this is news to you, small biotech may not be the appropriate place for you to be investing.

0 · Reply

Bo0977 Jun. 25 at 12:08 PM

$GANX losing Hope for this co. Ind is ???? Partnership and funding waiting on Ind ??? Our data good We are doing things that have never been done before We are probably a treatment for other neuro degenerative disorders as well Yet we fail to impress BP I have been patient but we have missed every timeline so far. Give us hope Gene How about some insider buying Or something!!!

2 · Reply

MQuick Jun. 25 at 12:02 PM

$GANX also the FDA is worthless

0 · Reply

MQuick Jun. 25 at 12:01 PM

$GANX what idiot is offering 10k at $1.75 pm? So frustrating, the constant games!

1 · Reply

Madmone Jun. 25 at 10:36 AM

$GANX the bullshit pumpers (Dave, Micro, JWA) talking about institutional dark pool acculmulation over the months and years is an out right lie.

2 · Reply

Layne_Thomas_Staley Jun. 24 at 9:48 PM

$GANX

0 · Reply

LolaPse Jun. 24 at 8:21 PM

$GANX The missed opportunity costs by holding this POS has cost everyone who owns thousands of dollars.

4 · Reply

MarkeTimer Jun. 24 at 8:03 PM

$GANX Another banner day for team anemic. Same time tomorrow knuckleheads.

1 · Reply

Chris2bucks4life Jun. 24 at 7:44 PM

$GANX another 1000 today orders are filling in seconds not good

1 · Reply

gatorsgrip Jun. 24 at 7:30 PM

$GANX Holding the 500 bar support at $1.75. The multi year trendline, hasn't been much of a factor over the last 6 weeks--$1.78-(incrementally going higher). Been passing thru that up/down relatively easily now. With regards to the FDA's timeline.....

1 · Reply

Jwelz90 Jun. 24 at 7:07 PM

$GANX Hey, its me watching the rest of Biotech this week while trying to stay an optimist.

1 · Reply

DonkeyClanbrands Jun. 24 at 6:31 PM

$GANX at least the fda is giving other companies love.. I know I know our day will come https://stocktwits.com/news-articles/markets/equity/galt-stock-surges-on-track-for-best-day-in-over-a-year-after-fda-clears-path-for-late-stage-belapectin-trial/cZKw9LfR7ax

1 · Reply

Market Cap	75.50M
Revenue (ttm)	0.00
Net Income (ttm)	-20.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	272,100
Avg Vol	604,916
Day's Range	N/A - N/A
Shares Out	42.65M
Stochastic %K	49%
Beta	0.16
Analysts	Strong Sell
Price Target	$7.20